Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$17,500.00

Assessment of Novel Risk Factors for Chronic Lung Allograft Dysfunction after Lung Transplantation

FY 2019-20

Summary
"Breathing is a ubiquitous action that most of us take for granted, but for patients with end stage lung diseases, every breath is a fight. For many of these patients, lung transplantation is the only treatment that can significantly prolong survival and improve quality of life.The most important limiter of long-term survival after this procedure is chronic lung allograft dysfunction (CLAD), which describes a range of disease processes in the airways and tissues of the transplanted lungs that lead to a persistent decline in lung function. Unfortunately, therapies for CLAD remain limited in their effectiveness once the disease has set in so a key focus has been prevention.Azithromycin is an antibiotic that can also help with treating lung diseases by reducing airway inflammation. Previous research on a small group of recipients has suggested that this drug decreases the risk of developing CLAD if given shortly after transplant and maintained thereafter. We want to see if this finding holds true in our much larger group of recipients and furthermore, study the direct relationship between preventative azithromycin use and overall survival following transplant.Of course, it is difficult to treat what one does not know, and much remains unknown about the exact mechanisms leading to CLAD. Ventilation-perfusion (VQ) scans show how airflow and blood flow are distributed in the lungs. These imaging studies provide insight on lung abnormalities but there has been little research on their implications specifically in lung transplant recipients. We want to know if any findings on the VQ scans of recipients at 3-months are associated with CLAD development later on. Identifying these early risk factors could shed light on how CLAD develops and allow for earlier intervention."
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
428942
Name
Li David J
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Assessment of Novel Risk Factors for Chronic Lung Allograft Dysfunction after Lung Transplantation
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Lung Diseases; Lung Transplantation; Pulmonary Medicine
Abstract
"Breathing is a ubiquitous action that most of us take for granted, but for patients with end stage lung diseases, every breath is a fight. For many of these patients, lung transplantation is the only treatment that can significantly prolong survival and improve quality of life.The most important limiter of long-term survival after this procedure is chronic lung allograft dysfunction (CLAD), which describes a range of disease processes in the airways and tissues of the transplanted lungs that lead to a persistent decline in lung function. Unfortunately, therapies for CLAD remain limited in their effectiveness once the disease has set in so a key focus has been prevention.Azithromycin is an antibiotic that can also help with treating lung diseases by reducing airway inflammation. Previous research on a small group of recipients has suggested that this drug decreases the risk of developing CLAD if given shortly after transplant and maintained thereafter. We want to see if this finding holds true in our much larger group of recipients and furthermore, study the direct relationship between preventative azithromycin use and overall survival following transplant.Of course, it is difficult to treat what one does not know, and much remains unknown about the exact mechanisms leading to CLAD. Ventilation-perfusion (VQ) scans show how airflow and blood flow are distributed in the lungs. These imaging studies provide insight on lung abnormalities but there has been little research on their implications specifically in lung transplant recipients. We want to know if any findings on the VQ scans of recipients at 3-months are associated with CLAD development later on. Identifying these early risk factors could shed light on how CLAD develops and allow for earlier intervention."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Li, David J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~